BioNTech’s ASCO 2025 oncology advances: New data on bispecific antibodies, ADCs & mRNA immunotherapies
Oncology
At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
The company’s chief commercial officer, Annemarie Hanekamp, sat down with web editor Nicole Raleigh to discuss the data and how it highlights continued clinical progress across BioNTech’s pipeline of oncology candidates, including bispecific antibodies, ADCs, and mRNA-encoded cancer immunotherapies.
Watch this and other conversations from ASCO 2025 here.
